aTyr pharma raises $23M Series C for new biologics.(Tuesday, Oct. 26)(Brief article)

Biologics pioneer aTyr Pharma inc. announced on Oct. 26 the close of its $23 million Series C financing. According to John Mendlein. San Diego-based aTyr's executive board chairman, the round closed quickly; was oversubscribed and provided a step-up in valuation - all feats that are difficult for preclinical companies in the current market. Investor interest was driven by aTyr's research on physiocrines, a newly discovered …